Harbright Ventures

🚀 Exciting News! The Wolfpack Investor Network and Harbright Ventures have made a follow-on investment of over $1.75M in SonoVascular, Inc., a medical technology company that has developed SonoThrombectomy™. SonoVascular’s innovative SonoThrombectomy™ System combines pharmaco-mechanical action, ultrasound facilitation, and thrombolytic enhancement to treat venous thromboembolism (VTE), which includes Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE). With VTE being the third most common cardiovascular disease and responsible for 300K annual deaths in the US, the potential impact of this technology is enormous. Special shoutout to NC State alumni John Ranshaw, Hannah Flores, and Drs. Xiaoning Jiang and Paul Dayton on this groundbreaking technology. Their work through the NC State and UNC-CH BME MS-TRAIN program shows the power of academic and entrepreneurial collaboration! 👏 SonoVascular’s system represents a breakthrough in treating life-threatening blood clots safely and efficiently, eliminating the need for ICU care. We're excited to support SonoVascular's journey to bring life-saving solutions to patients worldwide! 🌍 Read More Here: https://lnkd.in/ei-z77xZ #MedicalInnovation #VentureCapital #HealthTech #WIN #NCState #Investment #SonoVascular #VTE #DVT #PE #HealthcareInnovation #NCStateAlumni #NCStateFaculty

🚀 WIN Boosts Investment in Deep Blue Medical Advances 🚀 WIN is excited to announce a follow-on investment of $290K in Deep Blue Medical Advances, Inc., a pioneer in soft tissue surgery. Deep Blue has developed innovative soft tissue surgery products, including the T-Line® Hernia Mesh and T-Line® Tissue Control Suture. Leveraging intellectual property licensed from NC State, Deep Blue’s advancements aim to significantly reduce procedure time, lessen surgeon fatigue, minimize patient pain, and decrease the likelihood of requiring surgical remediation. Failures in soft tissue surgery, including hernia repairs, occur when pressures exceed the strength of the repair, leading to complications and high recurrence rates. In the U.S., these procedures are costly, with ventral hernia repairs costing approximately $10B annually. WIN is proud to support Deep Blue as they continue to drive innovation in medical technology. 💡 Read more here: https://lnkd.in/eAh3gJVV #VentureCapital #MedicalInnovation #SoftTissueSurgery #NCState #WIN

Last week, teams from Elevance Health (Amerigroup), Uber Health, Agilix Health, and Avēsis came together to review the incredible progress we're making with our maternal health program in Georgia. 🚀 Together, we are: 🤝 Enhancing Outcomes: By combining our expertise and resources, we're improving health outcomes for pregnant moms, ensuring they receive the care and support they need throughout their journey. 🚗 Improving Access: We're providing reliable transportation to prenatal and postnatal appointments, removing a critical barrier to care for many mothers. 🩺 Innovating Care Delivery: Advanced care coordination and technology, helping us deliver personalized and effective care to every expectant mother. 💡 Driving Impact: Our collaborative efforts are already showing positive results, with measurable improvements in maternal and infant health outcomes. This partnership is a testament to what we can achieve when we work together towards a common goal. Thank you to everyone involved for your dedication and hard work in making a difference in the lives of so many mothers and their babies! 💙👶 #MaternalHealth #HealthcareInnovation #Partnership #Elevance #UberHealth #Agilix #Avesis #GeorgiaHealthcare #BetterOutcomes

🚀 Exciting New Company Presentation Hosted by WIN  🎉 The Wolfpack Investor Network proudly announces that VQ Biomedical will present live to WIN's members. 🗓️ When: Wednesday, September 4th, 5:30 PM EST 📍 Where: NC State’s Centennial Campus 💻 Virtual Option: Join us via Zoom (6 PM) if you can't attend in person! VQ Biomedical's intravascular oxygenation catheter is a potential game-changer in treating Acute Respiratory Distress Syndrome (ARDS), a condition impacting ~400K patients annually across the U.S. and E.U. 🌍 ARDS deaths related to COVID-19 exceeded 50K in 2020….a 5X increase from historical averages. VQ Biomedical's technology could have helped many of these patients. Join us to hear from the VQ Biomedical team, including CEO Galen Robertson, CMO Dr. Tobias Straube, VP of R&D Patrick Sterlina, and co-founder/lead engineer Stewart Farling, as they share insights into their technology and its potential to transform patient care. Following VQ Biomedical's pitch, WIN's venture partner, Harbright Ventures, will present its Real-Win-Worth analysis. If you want to learn more about this innovative company and its latest developments, don't miss this event! RSVP here: go.ncsu.edu/vq_biomedical to attend in person or receive a Zoom link. For additional details or questions, feel free to contact Abby Phillips.